Giovanni Stelitano

, Via Ferrata 9
Pavia, 27100, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 32 publications

Rational Design of Diaryl Ether-Based Dual Inhibitors Targeting Successive Essential Enzymes HadAB and InhA in Mycobacterium tuberculosis.

Rational Design of Diaryl Ether-Based Dual Inhibitors Targeting Successive Essential Enzymes HadAB and InhA in Mycobacterium tuberculosis.

Journal: Journal of medicinal chemistry

Published: July 08, 2026

Screening of diphenylterephthalamide derivatives against Mycobacterium tuberculosis: an in silico and in vitro study.

Screening of diphenylterephthalamide derivatives against Mycobacterium tuberculosis: an in silico and in vitro study.

Journal: Bioorganic chemistry

Published: June 25, 2026

Dual SYK-HDAC Inhibitor Elicits Striking Efficacy against Acute Myeloid Leukemia: Rational Design, Synthesis, and Biological Evaluation.

Dual SYK-HDAC Inhibitor Elicits Striking Efficacy against Acute Myeloid Leukemia: Rational Design, Synthesis, and Biological Evaluation.

Journal: Journal of medicinal chemistry

Published: June 09, 2026

Special Issue "Molecular Research on Bacteria".

Special Issue "Molecular Research on Bacteria".

Journal: International journal of molecular sciences

Published: January 30, 2026

Uncovering Insights Into the Biology of Mycobacterium tuberculosis Using Genetic Tools.

Uncovering Insights Into the Biology of Mycobacterium tuberculosis Using Genetic Tools.

Journal: MicrobiologyOpen

Published: June 24, 2025

Advancing the antituberculosis activity of nitropicolinic acids and amides.

Advancing the antituberculosis activity of nitropicolinic acids and amides.

Journal: European journal of medicinal chemistry

Published: May 22, 2025

Mycobacterium tuberculosis Sulfate Ester Dioxygenase Rv3406 Is Able to Inactivate the RCB18350 Compound.

Mycobacterium tuberculosis Sulfate Ester Dioxygenase Rv3406 Is Able to Inactivate the RCB18350 Compound.

Journal: ACS infectious diseases

Published: March 20, 2025

Mycobacterium abscessus Virulence Factors: An Overview of Un-Explored Therapeutic Options.

Mycobacterium abscessus Virulence Factors: An Overview of Un-Explored Therapeutic Options.

Journal: International journal of molecular sciences

Published: March 06, 2025

Nanoenabling MbtI Inhibitors for Next-Generation Tuberculosis Therapy.

Nanoenabling MbtI Inhibitors for Next-Generation Tuberculosis Therapy.

Journal: Journal of medicinal chemistry

Published: March 03, 2025

Repurposing of FDA-Approved Drugs to Disrupt Iron Uptake in Mycobacterium abscessus: Targeting Salicylate Synthase as a Novel Approach.

Repurposing of FDA-Approved Drugs to Disrupt Iron Uptake in Mycobacterium abscessus: Targeting Salicylate Synthase as a Novel Approach.

Journal: Chemical biology & drug design

Published: February 06, 2025

Artificial Intuition and accelerating the process of antimicrobial drug discovery.

Artificial Intuition and accelerating the process of antimicrobial drug discovery.

Journal: Computers in biology and medicine

Published: October 24, 2024

Phage Therapy: An Alternative Approach to Combating Multidrug-Resistant Bacterial Infections in Cystic Fibrosis.

Phage Therapy: An Alternative Approach to Combating Multidrug-Resistant Bacterial Infections in Cystic Fibrosis.

Journal: International journal of molecular sciences

Published: June 19, 2024

Showing 1-12 of 32

Last Updated: 09/26/2026